<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847678</url>
  </required_header>
  <id_info>
    <org_study_id>MYC123A2201</org_study_id>
    <secondary_id>NTP/Mycograb/003B</secondary_id>
    <nct_id>NCT00847678</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS</brief_title>
  <official_title>A Multicenter, Randomized Study to Assess the Efficacy and Safety of Mycograb速 as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, efficacy and safety trial to evaluate Mycograb速. Subjects
      will be randomized to one of the 3 arms: 1/ Amphotericin B (0.7 mg/kg/d) plus 5-flucytosine
      (100 mg /kg/d); 2/ Amphotericin B plus Mycograb速 (dosed 1 mg/kg via a central line or
      peripheral venous line twice daily for 7 consecutive days); 3/ Amphotericin B plus
      5-flucytosine plus Mycograb速 (dosed 1 mg/kg via a central line or peripheral venous line
      twice daily for 7 consecutive days). After 2 weeks, all patients will be switched to
      fluconazole at 400 mg/d for 8 weeks and 200 mg/d thereafter. The total duration of the study
      will be approximately 24 months
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2006</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients (receiving Mycograb + Amphotericin B + 5-flucytosine) cured (combined clinical and microbiological response) versus placebo (Amphotericin B + 5-flucytosine) and versus Mycograb + Amphotericin B alone.</measure>
    <time_frame>day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Mycograb versus placebo. Safety assessment will include: physical examination, vital signs, laboratory parameters, adverse events, serious adverse events.</measure>
    <time_frame>week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the cerebrospinal fluid (CSF) penetration of Mycograb</measure>
    <time_frame>Days 3, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine whether Mycograb + Amphotericin B is as effective as Amphotericin B plus 5-cytosine while avoiding the potential problem of 5-cytosine toxicity.</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Cryptococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mycograb + Amphotericin B + 5 flucytosine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Amphotericin B + 5 flucytosine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mycograb + Amphotericin B</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Efungumab (Mycograb)</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Amphotericin B</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>5 flucytosine</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or non-pregnant female who is &gt; 18 years old.

          -  HIV-positive or unknown, with acute, either first or recurrent episode of cryptococcal
             meningitis.

          -  Currently on no treatment, or receiving treatment (&lt; 3 days) with either amphotericin
             B plus 5-flucytosine, or amphotericin B alone.

          -  Positive CSF culture for Cryptococcus neoforman.

          -  Physical signs and symptoms of meningitis, evidenced by one or more of the following:
             fever, headache, meningeal signs and neurologic findings.

        Exclusion criteria:

          -  Excluded for coma, or significant other medical conditions.

          -  Subject has other opportunistic fungal infections that requires other systemic
             antifungal therapies.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Africa</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <last_update_submitted>February 18, 2009</last_update_submitted>
  <last_update_submitted_qc>February 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Cryptococcal Meningitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Flucytosine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

